CKPT Stock Overview
A clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Checkpoint Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.19 |
| 52 Week High | US$3.62 |
| 52 Week Low | US$1.36 |
| Beta | 1.3 |
| 11 Month Change | -6.81% |
| 3 Month Change | 0.46% |
| 1 Year Change | 24.43% |
| 33 Year Change | -93.16% |
| 5 Year Change | -89.26% |
| Change since IPO | -95.62% |
Recent News & Updates
Recent updates
We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Sep 20
Checkpoint: Strong Data, But Comes With Risks
Sep 08Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M
Aug 12Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?
May 18Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions
Apr 18Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth
Feb 15Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results
Jan 28Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout
Nov 26Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans
Oct 30We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate
Jul 17Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data
Jul 14Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow
Jun 21Checkpoint surges 24% on B. Riley buy initiation, 567% upside potential
Jun 09It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year
Jun 02The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It
Mar 11Have Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Insiders Been Selling Their Stock?
Feb 06
Do Institutions Own Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares?
Jan 27Shareholder Returns
| CKPT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.4% | -0.1% | 0.8% |
| 1Y | 24.4% | 21.7% | 33.4% |
Return vs Industry: CKPT exceeded the US Biotechs industry which returned 21.7% over the past year.
Return vs Market: CKPT underperformed the US Market which returned 33.4% over the past year.
Price Volatility
| CKPT volatility | |
|---|---|
| CKPT Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CKPT has not had significant price volatility in the past 3 months.
Volatility Over Time: CKPT's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 23 | James Oliviero | checkpointtx.com |
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company’s lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Checkpoint Therapeutics, Inc. Fundamentals Summary
| CKPT fundamental statistics | |
|---|---|
| Market cap | US$100.84m |
| Earnings (TTM) | -US$42.47m |
| Revenue (TTM) | US$78.00k |
1,264x
P/S Ratio-2.3x
P/E RatioIs CKPT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CKPT income statement (TTM) | |
|---|---|
| Revenue | US$78.00k |
| Cost of Revenue | US$26.77m |
| Gross Profit | -US$26.69m |
| Other Expenses | US$15.77m |
| Earnings | -US$42.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | -34,223.08% |
| Net Profit Margin | -54,444.87% |
| Debt/Equity Ratio | 0% |
How did CKPT perform over the long term?
See historical performance and comparison